Late Gastrointestinal Toxicity During Nivolumab Therapy in Non-Small Cell Lung Cancer: A Rare Case of Inflammatory Bowel Disease

J Thorac Oncol. 2018 Aug;13(8):e152-e153. doi: 10.1016/j.jtho.2018.03.022.

Authors

Giorgia Guaitoli¹, Cinzia Baldessari², Chiara Tomasello², Fausto Barbieri², Stefano Cascinu², Federica Bertolini², Anna Maria Cesinaro³

Affiliations

¹ Department of Oncology and Haematology, Modena University Hospital, Modena, Italy. Electronic address: [email protected].
² Department of Oncology and Haematology, Modena University Hospital, Modena, Italy.
³ Department of Anatomic Pathology, Modena University Hospital, Modena, Italy.

PMID: 30049380
DOI: 10.1016/j.jtho.2018.03.022

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antineoplastic Agents, Immunological / adverse effects
Antineoplastic Agents, Immunological / therapeutic use
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / pathology
Humans
Inflammatory Bowel Diseases / chemically induced*
Inflammatory Bowel Diseases / pathology
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Male
Nivolumab / administration & dosage
Nivolumab / adverse effects*

Substances

Antineoplastic Agents, Immunological
Nivolumab